Cantor Fitzgerald Reiterates Overweight Rating, $19 Price Target on Exagen (XGN) on Alivio Health Agreement
Tweet Send to a Friend
Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $19.00 price target on Exagen (NASDAQ: XGN), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
